ERBB2 and breast cancer: Trastuzumab, a humanized antibody of HER2, is thought to be a successful strategy to block HER2 receptors when there is overexpression, thereby blocking growth of cancer and prolonging the overall survival of HER2+ breast cancer patients in adjuvant and metastatic settings [5,6].